Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 18/20 | 0.70 |
| ▸ | ADRB1 | P08588 | 3/20 | 0.63 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14505292 | 0.84 | ADRB2 (1.00) | ADRB2ADRB1ADRB3KDM4EGAA | |
| SCHEMBL4872831 | 0.81 | ADRB2 (0.54) | ADRB2ADRB1ADRB3 | |
| Hydrochloric Acid SCHEMBL11692252 | 0.81 | ADRB2 (0.48) | ADRB2ADRB1ADRB3KDM4E | |
| SCHEMBL11692156 | 0.79 | ADRB1 (0.57) | ADRB2ADRB1 | |
| SCHEMBL14030664 | 0.79 | ADRB2 (0.84) | ADRB2ADRB1ADRB3KDM4EGAA | |
| SCHEMBL5006903 | 0.77 | ADRB2 (1.00) | ADRB2ADRB1 | |
| SCHEMBL4867689 | 0.77 | ADRB2 (1.00) | ADRB2ADRB1 | |
| SCHEMBL4867697 | 0.77 | ADRB2 (1.00) | ADRB2ADRB1 | |
| SCHEMBL4862750 | 0.77 | ADRB2 (1.00) | ADRB2ADRB1 | |
| SCHEMBL4889035 | 0.77 | ADRB2 (1.00) | ADRB2ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7427639-B2 | β2-adrenergic receptor agonists | THERAVANCE, INC. (US) | 2008-09-23 | — | — | US | disclosed |
| US-20070179179-A1 | Beta2-adrenergic receptor agonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2007-08-02 | — | — | US | disclosed |
| US-7217738-B2 | β2-adrenergic receptor agonists | THERAVANCE, INC. (US) | 2007-05-15 | — | — | US | disclosed |
| US-7211695-B2 | β2-adrenergic receptor agonists | THERAVANCE, INC. (US) | 2007-05-01 | — | — | US | disclosed |
| US-7105701-B2 | β2-adrenergic receptor agonists | THERAVANCE, INC. (US) | 2006-09-12 | — | — | US | disclosed |
| US-20060183918-A1 | Beta 2-adrenergic receptor agonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2006-08-17 | — | — | US | disclosed |
| EP-1019075-B9 | BETA 2-ADRENERGIC RECEPTOR AGONISTS | THERAVANCE INC (US) | 2006-08-16 | — | — | EP | disclosed |
| US-20050261338-A1 | Beta2-adrenergic receptor agonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2005-11-24 | — | — | US | disclosed |
| US-20050209275-A1 | Beta 2-adrenergic receptor agonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2005-09-22 | — | — | US | disclosed |
| EP-1019075-B1 | BETA 2-ADRENERGIC RECEPTOR AGONISTS | THERAVANCE INC (US) | 2005-08-24 | — | — | EP | disclosed |
| US-20020055651-A1 | Beta2-adrenergic receptor agonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2002-05-09 | — | — | US | disclosed |
| WO-2001042193-A1 | β2-ADRENERGIC RECEPTOR AGONISTS | THERAVANCE, INC. (US) | 2001-06-14 | — | — | WO | disclosed |
| EP-1082289-A4 | METHODS FOR IDENTIFYING NOVEL MULTIMERIC AGENTS THAT MODULATE RECEPTORS | ADVANCED MEDICINE INC (US) | 2001-03-14 | — | — | EP | disclosed |
| EP-1082289-A1 | METHODS FOR IDENTIFYING NOVEL MULTIMERIC AGENTS THAT MODULATE RECEPTORS | Advanced Medicine, Inc. (US) | 2001-03-14 | — | — | EP | disclosed |
| EP-1019075-A4 | $g(b)2-ADRENERGIC RECEPTOR AGONISTS | ADVANCED MEDICINE INC (US) | 2000-12-13 | — | — | EP | disclosed |
| WO-1999066944-A9 | METHODS FOR IDENTIFYING NOVEL MULTIMERIC AGENTS THAT MODULATE RECEPTORS | ADVANCED MEDICINE INC (US) | 2000-07-27 | — | — | WO | disclosed |
| EP-1019075-A1 | $g(b)2-ADRENERGIC RECEPTOR AGONISTS | Advanced Medicine, Inc. (US) | 2000-07-19 | — | — | EP | disclosed |
| WO-1999064035-A9 | β2-ADRENERGIC RECEPTOR AGONISTS | ADVANCED MEDICINE INC (US) | 2000-07-06 | — | — | WO | disclosed |
| WO-1999066944-A1 | METHODS FOR IDENTIFYING NOVEL MULTIMERIC AGENTS THAT MODULATE RECEPTORS | ADVANCED MEDICINE, INC. (US) | 1999-12-29 | — | — | WO | disclosed |
| WO-1999064035-A1 | β2-ADRENERGIC RECEPTOR AGONISTS | ADVANCED MEDICINE, INC. (US) | 1999-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261338-A1 | Beta2-adrenergic receptor agonists | ADRB2, ADRB1, ADRA2B | ADRB2 1/4885ADRB1 2/4885ADRB3 4/4885 |
| US-20020055651-A1 | Beta2-adrenergic receptor agonists | ADRB2, ADRB1, ADRA2B | ADRB2 1/4885ADRB1 2/4885ADRB3 4/4885 |
| US-20050209275-A1 | Beta 2-adrenergic receptor agonists | ADRB2, ADRB1, ADRA2B | ADRB2 1/4885ADRB1 2/4885ADRB3 4/4885 |
| US-20060183918-A1 | Beta 2-adrenergic receptor agonists | ADRB2, ADRB1, ADRA2B | ADRB2 1/4885ADRB1 2/4885ADRB3 4/4885 |
| US-20070179179-A1 | Beta2-adrenergic receptor agonists | ADRB2, ADRB1, ADRA2B | ADRB2 1/4885ADRB1 2/4885ADRB3 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.